Gonul Ali Saffet, Kula Mustafa, Sofuoglu Seher, Tutus Ahmet, Esel Ertugrul
Department of Psychiatry, Ege University School of Medicine, Bornova, 35100 Izmir, Turkey.
Eur Arch Psychiatry Clin Neurosci. 2003 Feb;253(1):29-33. doi: 10.1007/s00406-003-0401-1.
Dopamine D(2) blocking typical antipsychotic drugs are known to change the cerebral perfusion patterns of schizophrenic patients, especially in the frontal cortex and basal ganglia. In recent years atypical antipsychotics such as olanzapine, which have high serotonin 5-HT(2A)/dopamine D(2) occupation ratios, have been shown to be more effective in the treatment of schizophrenia symptoms. The aim of this study was to evaluate the regional cerebral blood flow (rCBF) of the schizophrenic patients treated with olanzapine in a within-subject design. Twenty-four patients with schizophrenia participated as subjects in the study. Each subject was scanned in a medication-free state and after 6 weeks of 10 mg/day fixed dose olanzapine treatment. Despite the clinical improvement seen in the patients, repeated-measures analysis of variance showed that olanzapine produced no significant changes in cortical rCBF after the six-week treatment. This finding indicates that unlike typical antipsychotics olanzapine has no negative effect on cortical cerebral perfusion patterns of schizophrenic patients.
已知多巴胺D(2)受体阻断型典型抗精神病药物会改变精神分裂症患者的脑灌注模式,尤其是额叶皮质和基底神经节的灌注模式。近年来,诸如奥氮平这类5-羟色胺5-HT(2A)/多巴胺D(2)占据率高的非典型抗精神病药物,已被证明在治疗精神分裂症症状方面更有效。本研究的目的是采用受试者自身对照设计,评估接受奥氮平治疗的精神分裂症患者的局部脑血流量(rCBF)。24名精神分裂症患者参与了本研究。每位受试者在未服药状态下以及接受10毫克/天固定剂量奥氮平治疗6周后均接受了扫描。尽管患者的临床症状有所改善,但重复测量方差分析显示,六周治疗后奥氮平并未使皮质rCBF产生显著变化。这一发现表明,与典型抗精神病药物不同,奥氮平对精神分裂症患者的皮质脑灌注模式没有负面影响。